Drug Clinical Trials List
Drug Clinical Trials List
| Study Title | Study Sponsor | Status | Study Drug | Trial Phase | Study Protocol Number | Site |
|---|---|---|---|---|---|---|
| Superiority of Insulin Glargine Lantus vs. NPH: Treat to Normoglycemia Concept.Effect of Insulin Glargine in Comparison to Insulin NPH in Insulin-nave People With Type 2 Diabetes Mellitus Treated With at Least One OAD and Not Adequately Controlled | Sanofi | Completed | Lantus® | 3 | LANTU_C_02762 | KFUH |
| "Study to Evaluate the Safety, Tolerability and Immunogenicity of INO-4700 for Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in Healthy" | Inovio Pharmaceuticals, Inc. | Completed | NO-4700 + CELLECTRA™ 2000 (device) | 2 | MERS-201 | KSMC |
| Study of Aflibercept in Uveitic Macular EDema (SAUD study) | King Khalid Specialist Hospital | Rejected | Aflibercept | 3b | 18176 | KKESH |
| "Study H9X-MC-GBGC is a Phase 3, randomized, double-blind, placebo-controlled trial with an open-label extension that investigates the effect of the addition of dulaglutide (0.75 and 1.5 mg/week) or placebo weekly to metformin and/or basal insulin on change from baseline in hemoglobin A1c at 26 weeks in children and adolescents with type 2 diabetes mellitus" | Eli Lilly | Ongoing | Dulaglutide 0.75 /1.5 mg | 3 | H9X-MC-GBGC | KKUH |
| Standard Induction with Basiliximab versus No-Induction in Low Immunological Risk Kidney Transplant Recipients Prospective Randomized Double Blind Controlled Clinical Trial | King Faisal Specialist Hospital and Research Centre | Ongoing | BASILIXIMAB (SIMULECT) | 3 | 2191177 | King Faisal Specialist Hospital and Research Center (Riyadh) |
| SPIMACO Biosimilar Insulin Phase III Study: Clinical Efficacy and Safety | SPIMACO | Ongoing | Fastulin R / Normulin N | 3 | N/A (version 1.4) Aug 2011 | KFMC |
| "Somatostatin as inflow modulator in Adult-to-Adult living donor liver transplantation. A randomized, double-blind, placebo-controlled trial" | King Faisal Specialist Hospital and Research Centre | Ongoing | Somatostatin | 3 | 2191109 | KFSH & RC-R |
| Single arm Phase I/II study of the safety, tolerability and efficacy of the Tocilizumab followed by cisplatin/docetaxel in patients with triple negative locally advanced breast cancer | King Faisal Specialist Hospital and Research Centre | Ongoing | TOCILIZUMAB (ACTEMRA) | 1/2 | 2181156 | KFSH&RC-R |
| Single arm Phase I/II study of the safety, tolerability and efficacy of the investigational anti PD-L1 monoclonal antibody Durvalumab in combination with Paclitaxel in patients with metastatic triple negative PD-L1 positive breast cancer | AstraZeneca | Ongoing | Paclitaxel | 1, 2 | ESR-14-10649 | KFSH & RC-R |
| Safety and Feasibility of CD19 Chimeric Antigen Receptor (CAR) T Cells In Adults with CD19 Positive Relapsed and Refractory Acute Lymphoblastic Leukemia or Lymphoma | KAIMRC | Completed | CD19-CART | 1b | RC20/446/R | NGHA-R |